Generation Bio

Generation Bio Financing Cash Flow

Delisted

The Net Financing Cash Flow of Generation Bio (GBIO) as of Nov 10, 2026 is 250,000.00 USD. In the previous year, Net Financing Cash Flow was 35.82 M USD — a change of -99.30% (lower).

Financing Cash Flow

250,000.00USD

YoY

-99.30%

Last updated:

Net Financing Cash Flow of Generation Bio is 2024 250,000.00 USD. Net Financing Cash Flow of Generation Bio was 2023 35.82 M USD. It decreases by -99.30% lower compared to the previous year.

The Generation Bio Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
100.19 M USD
Jan 1, 2019
78,000.00 USD
Jan 1, 2020
323.10 M USD
Jan 1, 2021
214.67 M USD
Jan 1, 2022
12.99 M USD
Jan 1, 2023
35.82 M USD
Jan 1, 2024
250,000.00 USD
The Generation Bio Financing Cash Flow history
YEARFinancing Cash FlowYoY
250,000.00USD-99.30%
35.82 MUSD+175.75%
12.99 MUSD-93.95%
214.67 MUSD-33.56%
323.10 MUSD+414,124.36%
78,000.00USD-99.92%
100.19 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Net Financing Cash Flow of Generation Bio is 250,000.00 USD in 2024.

Net Financing Cash Flow of Generation Bio changed from 35.82 M USD to 250,000.00 USD, representing a -99.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Generation Bio since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Generation Bio

All Key Metrics — Generation Bio